Tag Archives: AWD

PRNews

Frost & Sullivan Honors Linguamatics for Developing a Best-in-Class NLP-based Data Mining Platform for the Healthcare Industry

I2E makes natural language processing-based text mining intuitive and interactive

SANTA CLARA, California, July 20, 2017 /PRNewswire/ — Based on its recent analysis of the Big Data text analytics market for the healthcare industry, Frost & Sullivan recognizes Linguamatics with the 2017 Global Frost & Sullivan Award for Enabling Technology Leadership. Linguamatics stands out in the natural language processing (NLP) market for its technology expertise and commitment to delivering exceptional value to clients in the US healthcare industry. The highly flexible and scalable Linguamatics Health platform, powered by I2E, is helping healthcare providers and payers to transition to value-based care.

Within the last year, Linguamatics introduced its fifth iteration of I2E, which includes cutting-edge capabilities such as the normalization of concepts and relationships for quick and comprehensive data retrieval regardless of format; advanced range research; and an extraction and search query language (EASL). The EASL can be generated external to the platform to support custom interfaces, queries in a human-readable format, and superior workflow automation.

“Linguamatics I2E is designed to identify the various nuances of language, such as understanding the difference between ‘history of cancer’ and ‘family history of cancer.’ Further, the I2E 5.0 release identifies precise numerical information in context, like the tumor size and medication dosages,” said Frost & Sullivan Transformational Health Principal Industry Analyst Victor Camlek. “The platform can cluster and categorize multiple concepts based on plugged-in terminologies, thesauri, or ontologies. It finds the perfect balance between linguistic context and medical text negation, ensuring that a search of ‘no evidence of pneumonia’ does not result in a diagnosis of ‘pneumonia.'”

Linguamatics also recently introduced the I2E Asynchronous Messaging Pipeline (I2E AMP) to help healthcare professionals find critical clinical insights faster. With I2E AMP, the Linguamatics platform can automate the Big Data mining of streams of data across multiple servers, providing organizations with scalability as their NLP text mining requirements grow.

Linguamatics I2E is highly flexible and can mine data from many types of data sources, including electronic health records (EHRs), clinical trial and news feeds, medical literature, social media, and lifestyle data. The platform can be deployed as an in-house enterprise system, as a value-add enterprise search capability, or as a software-as-a-service (SaaS) on the cloud. In addition to real-time processing of Big Data, I2E also provides powerful linguistic and data exploration techniques that allow patterns of language to be explored and new ontologies to be boot-strapped from basic principles, such as representations of social determinants of health within discharge summaries.

Linguamatics collaborates closely with health systems to incorporate functionalities that reduce physicians’ manual efforts, while providing real-time point-of-care clinical decision support. The platform provides varied inquiry options, ranging from entity extraction to complete linguistic analysis. An entire patient profile can be built using the right combination of smaller queries, and intelligent searches can lead to the creation of smart queries that can be deployed for a larger user base.

“With its flexibility, transparency, and speed, the I2E platform gives users complete control so they can refine searches on-the-go,” noted Camlek. “Query creation is completely configurable, ensuring that clinical users or business users do not need to be NLP or technical experts. Additionally, for advanced searches, an intuitive drag-and-drop graphical interface helps users view and manage the required queries.”

Overall, for developing a technology that a wide range of companies in the healthcare industry can adopt to create better solutions for their customers, Frost & Sullivan is pleased to present Linguamatics with the 2017 Global Frost & Sullivan Award for Enabling Technology Leadership.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of newer products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Linguamatics

Linguamatics transforms unstructured big data into big insights to advance human health and wellbeing. A world leader in deploying innovative natural language processing (NLP)-based text mining for high-value knowledge discovery and decision support, Linguamatics’ solutions are used by top commercial, academic and government organizations, including 18 of the top 20 global pharmaceutical companies, the US Food and Drug Administration (FDA) and US National Cancer Institute, Cancer Research UK, and leading US healthcare organizations.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

PRNews

Frost & Sullivan Lauds eClinicalWorks for Providing Best-in-class RCM Services to a Wide Range of Independent and Hospital-acquired Physician Practices

eClinicalWorks’ large team of skilled professionals and ecosystem partners ensures hassle-free operation of its RCM services

SANTA CLARA, Calif., July 19, 2017 /PRNewswire/ — Based on its recent analysis of the ambulatory revenue cycle management (RCM) market, Frost & Sullivan recognizes eClinicalWorks with the 2017 North American Frost & Sullivan Award for Customer Value Leadership. eClinicalWorks pioneered a cost-effective, streamlined approach to billing in the ambulatory RCM market with its integrated cloud-based solution. For 2.9% of the monthly collection, it offers physicians comprehensive billing solutions, and prevents existing customers of electronic health record (EHR)/patient heath management/hospital management/patient engagement/cloud services from outsourcing billing services to external vendors. eClinicalWorks’ solutions integrate seamlessly with other proprietary health IT applications, allowing key provider executives to measure and monitor billing performance through unified dashboard reporting, powered by predictive financial analytics.


Frost & Sullivan recognizes eClinicalWorks with the 2017 North American Customer Value Leadership Award.

Click here to read the full Award Write Up – http://bit.ly/2uAagpJ

eClinicalWorks’ cloud-based solution boasts an uptime of 99.9% and has achieved a 98% first-pass acceptance for practice claims. It incorporates both the national rules engine, as well as the company’s own rules engine, so that reimbursements are evaluated efficiently and physician practices become eligible for various payer and state incentives.

“The company has assembled progressive technology modules that digitize the entire billing ecosystem end-to-end. It performs patient insurance eligibility assessment in real time, manages denials, investigates reasons for underpayments, periodically updates database rules, and automates the process of claims adjudication,” said Frost & Sullivan Industry Analyst Koustav Chatterjee. “eClinicalWorks’ built in RCM console also allows customers to monitor claims volumes at an enterprise level.”

Significantly, RCM operations largely require professionals with expertise in optimizing billing and collection for the cost incurred during patient care. eClinicalWorks’ highly skilled billing experts and ecosystem-level partners that have high-value technical capabilities in coding compliance, coding validation, bank reconciliation, and collection ensure that customers do not have to seek third-party help.

“eClinicalWorks is also widely popular among physician practices because of its round-the-clock and customer-friendly service. Dedicated account management teams carefully assess customer queries raised for patient registration, claims processing, and final collection, and make sure that payer reimbursement or self-payments made by patients are delivered directly to providers,” noted Chatterjee. “Technology, coupled with custom service capabilities, are helping eClinicalWorks garner optimum success in this service line.”

eClinicalWorks is a proven leader in the US ambulatory EHR market with an estimated market share of 10.2%, second only to Epic with 11.2%. The company offers advanced health IT solutions to almost 125,000 physicians and nurse practitioners, and its various service lines are used by more than 850,000 providers across all 50 US states, and globally in 20 countries.

For its ability to aid physicians with all their RCM needs and comply with regulations, Frost & Sullivan is pleased to present eClinicalWorks with the 2017 North American Frost & Sullivan Award for Customer Value Leadership.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the company’s inordinate focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention, and, ultimately, customer base expansion.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About eClinicalWorks

eClinicalWorks® is a privately held leader in healthcare IT solutions. With more than 125,000 physicians and nurse practitioners using its solutions, customers include ACOs, physician practices, hospitals, community health centers, departments of health, and convenient care clinics. During the past eight years, 16 eClinicalWorks customers have received the prestigious HIMSS Davies Award, honoring excellence in electronic health record implementation. The company is second largest in the country for e-prescribing. Based in Westborough, Mass., eClinicalWorks has additional offices in Austin, New York City, Chicago, California, Georgia, London, India, and Dubai. For more information, please visit www.eclinicalworks.com, Facebook, Twitter or call 866-888-6929.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Samantha Park
P: +1 210.247.2426
F: +1 210.348.1003
E: samantha.park@frost.com

Photo – https://mma.prnewswire.com/media/537159/Frost_Sullivan_eClinicalWorks_Award.jpg

PRNews

Frost & Sullivan Commends Oracle’s Expertly Engineered Unified Healthcare Analytics Platform, Oracle Healthcare Foundation

-Oracle Healthcare Foundation is the ideal tool to support the healthcare industry’s current and future data integration and data quality challenges

SANTA CLARA, California, July 19, 2017 /PRNewswire/ — Based on its recent analysis of the health data warehousing market, Frost & Sullivan recognizes Oracle Health Sciences with the 2017 North American Frost & Sullivan Award for Product Leadership. Stepping out of its IT industry stronghold, Oracle has engineered a highly organized version of its data warehouse, Oracle Healthcare Foundation (OHF), for the special needs of the healthcare industry. The solution’s unified analytics platform processes traditional clinical and claims data, financial and operational data and supply chain, human resources, administrative, and operational functions.


Oracle

Oracle Healthcare Foundation is a feature-rich analytics platform that supports more than 35 subject areas relevant to health data analytics, giving healthcare providers more granular data regarding the requirements of individuals and populations. They can use this data to effect process changes and quality improvement initiatives as well as leverage its out-of–the-box self-service analytics tools to build customized analytics solutions.

“The solution’s comprehensive, scalable, end-to-end platform enables data acquisition, validation, integration, warehousing, and analytics. It encompasses all data types and sources, delivering clinical, financial, administrative, and omics modules,” said Frost & Sullivan Principal Analyst for Digital Health Nancy Fabozzi. “It facilitates rigorous data integration, data governance, and data quality, driving greater engagement and adoption by operations, financial management, and clinical care delivery teams across the healthcare enterprise.”

Oracle Healthcare Foundation can be deployed as a complete or modular solution and as an on-premise, cloud, or hybrid solution, all depending on the customer’s unique needs.

“We strive to provide our customers with a range of capabilities that deliver a solid, stable and reliable core data foundation that will enable them to propel their healthcare businesses forward and scale to their future data analytics needs,” said Jonathan Sheldon, Global Vice President, Oracle Health Sciences.

Oracle understands that scientific advancement is resulting in new complex data types such as genome sequencing that need to be incorporated into the data warehouse and made available for clinical decision making. For this to happen successfully, the data warehouse must have the capacity to expand in a way that keeps the data footprint consistent and not leave any gaps. Oracle has made optimum use of its technology expertise and resources to reduce the amount of time and effort needed to set up and maintain a robust data warehouse.

“A stable data warehouse can reduce the effort required to tie together all of the customer’s data resources, normalize data, map new pieces of data or data types, and so on,” noted Fabozzi. “With Oracle Healthcare Foundation, all of this takes place in one stable solution, automated so that relatively few people are required to maintain it once it is set up. In doing so, Oracle allows its customers to shift essential human resources to higher value analytics activities instead of engaging them in connecting a data feed or finding an appropriate analytics application.”

Oracle strives for a very collaborative relationship with its customers and together, they drive the product roadmap. This partnership ensures that as Oracle builds out the data model and requirements, customers stay informed and the solution always meets their needs.

Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Oracle
The Oracle Cloud delivers hundreds of SaaS applications and enterprise-class PaaS and IaaS services to customers in more than 195 countries and territories while processing 55 billion transactions a day. For more information about Oracle (NYSE:ORCL), please visit us at oracle.com.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:
Estefany Ariza
P: 210.477.8469
F: 210.348.1003
E: estefany.ariza@frost.com

PRNews

Frost & Sullivan Applauds CORAnet™’s Efforts to Strengthen its Brand in the Competitive Mobile Electronic Health Record Market

CORAnet™ Solutions facilitate interoperability across networks and platforms, giving patients and their families ownership and personal control of their medical records

SANTA CLARA, California, July 17, 2017 /PRNewswire/ — Based on its recent analysis of the mobile electronic health record (EHR) market, Frost & Sullivan recognizes CORAnet™ with the 2017 North America Frost & Sullivan Award for Competitive Strategy Innovation and Leadership. CORAnet™ has emerged a successful, cloud-based mobile technology solution provider, offering first responders, doctors, and individual patients 24/7 secure access to personal health records (PHRs). Its advanced software makes possible real-time access to EHR data that is exchangeable along the entire care continuum. This capability is the result of its deep understanding of sophisticated EHR healthcare information technology, health information exchanges, mobile applications, HIPAA and MU3 compliance requirements.

The greater focus on patient engagement due to the shift toward value-based care has heightened the demand for mobile PHR solutions. CORAnet™ has expertly tapped the opportunities in the market by not only delivering novel EHR solutions but also introducing an emergency medicine platform; an ambulatory platform that provides on-demand access to disparate, consolidated and organized PHRs; and a mobile telemedicine platform that offers remote access to care anywhere.

“When using the CORAnet™ solution, individual patients cannot alter any source-identified health information originating from an EHR system. This guarantees data integrity. Users may, however, add or delete diagnosed allergies, thereby safeguarding against contraindications to medications not otherwise annotated,” said Frost & Sullivan Vice President of Global Life Sciences Nitin Naik. “In addition, if the patient wishes to share EHR data using an email address, the system can generate a PDF file that is password protected.”

CORAnet™’s unique mobile solution is enabled by fully interoperable servers that facilitate access to any EHR system, projecting data in a visual, encrypted format. Outstanding features of the CORAnet™ mobile platform include:

  • A patient-facing, EHR-agnostic solution that allows EHR companies, providers, and health facilities to keep their own proprietary data
  • Aggregation of an individual’s PHR from all health system sources into medical data sets such as medical history, x-rays, laboratory results, and plan of care
  • The ability for the patient to update information on vitals, medications, allergies, and dietary supplements consumed

“CORAnet™ has emerged as an innovative technology leader that widens access to PHRs with a system comprising two demonstrative elements: the ability to integrate information from multiple EHR systems, and the ability to deliver an integrated PHR to consumer mobile devices,” said Naik. “These advantages, along with patient engagement capabilities such as appointment setting, reminders, and the option to view and share imaging files, set CORAnet™ apart as an organization that adds significant value in the new field of care collaboration.”

With more sophisticated application providers designing mobile-ready solutions, the mobile “open way” may quickly become the designated entry point for patients and doctors to access personal health data. Frost & Sullivan commends CORAnet™ for delivering a mobile exchange to support interaction, including interoperability, using multiple sensors and monitors.

“Instant access to a patient’s complete health records via CORAnet allows individuals to manage their healthcare, have peace of mind, and can minimize medical errors, hospital readmissions, and reduce costs. For providers, CORAnet is an efficient, economical tool to improve healthcare delivery and outcomes, and compliance with federal Meaningful Use (MU3) mandate for electronic health records (EHR/EMR),” said CORAnet Solutions President & CEO Cora Alisuag.

Each year, Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to successfully execute a competitive strategy that results in stronger market share, competitive brand positioning, and customer satisfaction.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About CORAnet™

CORAnet™ Solutions, Inc. specializes in bringing mobile innovative solutions to the health care industry in the area of health management, electronic health records support, telemedicine and biometrics data predictive analytics.  CORAnet™ addresses the challenge of inefficiencies of health care by providing the interoperability, security, functionality, availability and mobility of health records. Contact us.

Contact:

P: 240 644 1555
E: info@coranetsolutions.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

PRNews

Mariana Geralde is Recipient of 2017 Basic PDT Research Excellence Award

COIMBRA, Portugal, July 14, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Mariana Geralde was the recipient of the 2017 BASIC PDT RESEARCH EXCELLENCE AWARD.

Mariana Geralde was recognized for research excellence at the Sao Carlos Institute of Physics (Brazil) for her work involving the clinical application of Photodynamic Therapy (PDT) as a method to treat pulmonary infections through extracorporeal illumination. This innovative research has resulted in the significant advancement of both PDT protocols and clinical outcomes, accelerating the potential for PDT treatment of multi-drug resistant pneumonia.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies. The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

please contact: ipasecretary@internationalphotodynamic.com

Logo – http://mma.prnewswire.com/media/535806/International_Photodynamic_Association_Logo.jpg

PRNews

Mr. Colin Hopper Receives IPA Lifetime Achievement Award in PDT Clinical Research

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Mr. Colin Hopper was the recipient of the 2017 LIFETIME ACHIEVEMENT AWARD IN PDT CLINICAL RESEARCH.

Mr. Colin Hopper is currently the Senior Lecturer/Consultant Oral and Maxillofacial Surgeon and unit head off oral and maxillofacial surgery at University College London (UCL), Eastman Dental Institute London.  He is a Consultant Head and Neck Surgeon, University College London Hospitals and until recently Senior Research Fellow at the National Medical Laser Centre London.

Mr. Hopper spent his early career pioneering clinical protocols to confirm safety and efficacy of PDT for oncological and antimicrobial applications. Since 1991, Mr. Hopper has been working in the National Medical Centre leading a variety of research projects on the use of photodynamic therapy in the treatment of oral squamous cell carcinoma. This clinical PDT program is currently one of the world’s largest and longest running programs, documenting over 400 treatments involving the three main photosensitizers.

Mr. Hopper, long recognized for his expertise in clinical PDT, is the principal investigator on a series of ethically approved projects, including in a number of developing countries. His work has resulted in numerous publications helping to establish a clear role for PDT treatment in a variety of neoplastic conditions in the head and neck. This work has advanced rapidly by the development of interstitial treatment of tumours using image guidance systems developed with the department of imaging and medical physics.  Other related areas of research include fluorescence diagnostics (optical techniques for tissue interrogation), the use of PDT in the treatment of non-malignant conditions such as lymphangioma and the use of PDT for antimicrobial applications. Mr. Hopper dedicates considerable personal time to lecturing, mentoring and training next generations of PDT clinicians globally.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

please contact: ipasecretary@internationalphotodynamic.com

PRNews

Dr. Pilar Acedo Nunez is Recipient of 2017 IPA Early Investigator Award

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Dr. Pilar Acedo Nunez was the recipient of the 2017 IPA EARLY INVESTIGATOR AWARD.

Dr. Pilar Acedo Nunez was recognized for her exceptional research at the University College London (England) involving combination photosensitizers and photodynamic therapy which demonstrated improved efficacy and response rates in vitro and in vivo. She has been awarded several research grants, prizes and awards including a competitive two-year postdoctoral fellowship (2015) sponsored by Ramon Areces Foundation (Spain) and the Peter Samuel Royal Free Trust Fund (UK) to study at UCL under Professor Sandy MacRobert and Professor Steve Pereira.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

PRNews

Dr. Natalia Inada is Recipient of 2017 Award for PDT Clinical Trial Excellence

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Dr. Natalia Inada was the recipient of the 2017 AWARD FOR PDT CLINICAL TRIAL EXCELLENCE.

Dr. Natalia Inada was recognized for her leadership and fundamental role over a number of innovative Photodynamic Therapy (PDT) based trials at the Institute of Physics of Sao Carlos (Brazil). These multi-centre clinical trials involve hundreds of Latin American patients and relate to the non-surgical PDT-based treatment of skin cancer and the non-surgical PDT-based treatment of cervical intraepithelial neoplasia (CIN), for the prevention of cervical cancer. These Photodynamic treatment protocols are intended to offer minimally invasive, superior outcomes for patients in underdeveloped countries with limited public health systems. Dr. Inada was also the recent recipient of the Mercosul Science and Technology Award for the “CerCa 150 System®: a non-surgical option for cervical intraepithelial neoplasia and condyloma treatment”.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies. The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

PRNews

Professor Brian Wilson Receives IPA Excellence Award In Photodiagnostic Research

COIMBRA, Portugal, July 11, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Professor Brian Wilson was the recipient of the 2017 EXCELLENCE AWARD IN PHOTODIAGNOSTIC RESEARCH.


Professor Brian Wilson

Dr. Brian Wilson is Professor of Medical Biophysics at Princess Margaret Cancer Centre/University Health Network, University of Toronto, Canada. He is a well-known expert and leader in the field of PDT and Photodiagnostics, internationally recognized for his pioneering research into various optic tools that can be used for minimally-invasive cancer treatment, and early diagnosis and optically-guided cancer therapeutics. He holds several awards in biomedical optics (Mark Award, NIH Translational Research Award, Michael S. Feld Award and Britton Chance Award) and in cancer research (Robert L. Noble Prize).

In 1981, Dr. Wilson initiated translational research and collaborative clinical trials of photodynamic therapy for brain, prostate and gastrointestinal cancers. Dr. Wilson leads a world-renowned R&D program in optics-based biomedical applications, with a primary translational/clinical focus. He has driven the development of fluorescence and other endoscopic imaging techniques – particularly in Barrett’s esophagus and colon cancer – and more recently has developed optical imaging to guide surgery that is being evaluated in clinical trials for head and neck, prostate and brain cancers. In the last few years, his research has expanded to include development of photonic nanoparticles in cancer treatment, diagnosis and research. Dr. Wilson has published over 350 peer-reviewed papers in basic, translational and clinical research. With several international Visiting Appointments (Harvard, USA; Saõ Paulo, Brazil; Fujian, China; Western Australia), Dr. Wilson is involved in many national and international collaborations. Dr. Wilson has trained more than 50 graduate students, post-doctoral and clinical fellows, many of whom remain in biomedical optics, cancer research and practice worldwide. He also has worked with many companies nationally and internationally in translating optical technologies into clinical practice.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

PRNews

Burjeel Hospital Wins ‘2017 UAE Emerging Medical Tourism Service Provider of the Year – Hospital Category’ Award at the 2017 Frost & Sullivan Middle East Best Practices Awards

DUBAI, United Arab Emirates, July 6, 2017 /PRNewswire/ — Burjeel Hospital (A unit of VPS Healthcare) was named ‘2017 UAE Emerging Medical Tourism Service Provider of the Year- Hospital Category‘ at the 2017 Frost & Sullivan Middle East Best Practices Awards Banquet held on 24th May at Atlantis, The Palm in Dubai.


Dr. Raja Gujju, Chief Operating Officer & Dr.Nabil Debouni, Medical Director, Burjeel Hospital receives the 2017 UAE Emerging Medical Tourism Service Provider of the Year – Hospital Category Award from Mr. Jamal Ramadhan Bin Marghoob, Director Marketing & Corporate Communications, from Dubai Airport Freezone in presence of Mr. Sandeep Sinha, Vice President, Transformational Health Practice, Frost & Sullivan

Burjeel Hospital Abu Dhabi is an emerging medical tourism service provider in the UAE. It caters to the growing medical needs of the UAE and GCC by offering high quality care in all medical specialties. The top five specialties in Burjeel Hospital Abu Dhabi, for international patients, include obstetrics, gynecology, orthopedics, neonatology, general surgery and gastroenterology. It offers special packages for cesarean section, bariatric surgery and hip replacement. Established in 2012, the hospital is currently expanding its operational beds to accommodate the growing needs of the local and international populace.

“We are truly honored to be recognized in this category by Frost & Sullivan this year. The award underlines our commitment as an organization to provide the best healthcare in the region and significantly contribute in enhancing the area of medical tourism in the UAE,” said Dr. Raja Gujju, Chief Operating Officer, Burjeel Hospital – Abu Dhabi.

Congratulating Burjeel Hospital Abu Dhabi on the award, Mr. Sandeep Sinha, Vice President, Transformational Health Practice, Frost & Sullivan said, “2016 has been a very successful year for Burjeel Hospital Abu Dhabi. The company’s international patient department contributed 34 percent to the total revenue of the hospital with an inflow of more than 8,000 international patients. The hospital not only provides world-class tertiary healthcare in the region, it also enhances the patient’s experience by managing their logistic needs, including visa and travel arrangements, hotel stays, dietary services, religious needs and airport transfer, thus delivering a stress-free experience. Its growth, unique services, marketing initiatives, technical advancements and the compassionate patient-centric approach are some of the key factors which have contributed to its leading position in the region.”

Frost & Sullivan Awards recognize companies across regional and global markets for outstanding achievement and performance in a range of regional and global markets for superior leadership, technological innovation, customer service, strategic product development among others.

Frost & Sullivan’s robust research methodology represents the analytical rigor of our research process. It offers a 360-degree-view of industry challenges, trends, and issues by integrating all 7 research methodologies. Too often, companies make important growth decisions based on a narrow understanding of their environment, leading to errors of both omission and commission. Successful growth strategies are founded on a thorough understanding of market, technical, economic, financial, customer, best practices, and demographic analyses. The integration of these research disciplines into the 360-degree research methodology provides an evaluation platform for benchmarking industry players and for identifying those performing at best-in-class levels.

About Burjeel Hospital

Burjeel Hospital is Abu Dhabi’s premier private healthcare facility providing world-class, specialized and superior healthcare complemented by a warm and personalized human touch to the growing population of the emirate of Abu Dhabi.

A unit of the VPS Healthcare, Burjeel Hospital opened for patients in April 2012 as a Tertiary hospital under the auspices of the Health Authority for Abu Dhabi.  At the core of the organization is a team of exceptionally skilled and highly experienced health professionals, collaborating as multidisciplinary teams with guests and their families as the main focus, to provide the best healthcare experience. 

Burjeel Hospital received the prestigious Joint Commission International (JCI) accreditation in June 2013 – 15 months after starting operations and the hospital was granted JCI Re-accreditation in Aug 2016. Currently, the hospital is affiliated with some of the world’s best healthcare institutions for its centers of excellence and is now becoming a renowned center of referral for Cardiovascular, Orthopedics, Ophthalmology, Pediatrics, Obstetrics and Gynecology, Reproductive Medicine, Oncology and many more specialties handling complex laparoscopic and minimally invasive surgeries. The hospital has full-fledged pharmacy, laboratory, and radiology units to serve guests at any time of the day. Burjeel also houses a restaurant and a coffee shop, serving the finest and healthiest cuisines from across the world. Combining all-round specialization and expertise with most advanced technology, Burjeel offers the best in diagnostic, curative, as well as preventive aspects of healthcare.

For more details, visit the website at www.burjeel.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

For Frost & Sullivan

Anita Chandhoke
Corporate Communications
C: +91 99161 33311
P: +91.80.6702 8020
E: achandhoke@frost.com
http://www.frost.com

For Burjeel Hospital

Joanne Rico
Marketing and Business Development Department
C: +971 8841 669
P: +971 2 508 5656
E: joanne.rico@burjeel.com 
www.burjeel.com

Photo – http://mma.prnewswire.com/media/530941/Burjeel_Hospital_Frost_Sullivan_Award.jpg